Chronic Myeloid Leukaemia

Exam Cram

• Cancer of myeloid cells in bone marrow (leukaemia), philadelphia chromosone 12, BCR-ABL

• Management: imatinib (tyrosine kinase inhibitor)

Management

1. Imatinib

Only 5% risk of disease progression over 5 years, with survival 90%. 

References and Resources

Written in 2025